LSD for Anxiety Could Be Approved in 2027

September 25, 2026

🧪 Clinical LSD Is Measured. Street LSD Isn't.

Trial participants know exactly what they're taking and how much. A tab from outside a study comes with no such guarantee. Screen for identity with reagents before you ever think about dose.

Explore LSD Testing Tools →

A pharmaceutical form of LSD has now reduced anxiety symptoms in two large late-stage clinical trials, positioning its developer, Definium, to seek FDA approval in 2027.

The treatment, called DT120, is a fast-dissolving tablet containing lysergide, the pharmaceutical name for LSD. Unlike medications taken every day, DT120 was administered once during a monitored dosing session.

The results could move LSD closer to becoming an approved anxiety treatment in the United States. That approval is not guaranteed, and the findings have so far been announced by the company rather than published as complete peer-reviewed trial results.

What the Second LSD Anxiety Trial Found

The second Phase 3 trial included 245 adults with generalized anxiety disorder. Participants received either 100 micrograms of DT120, a lower 50-microgram dose or a placebo.

After 12 weeks, the group receiving 100 micrograms showed an average 9.8-point reduction on the Hamilton Anxiety Rating Scale. The placebo group improved by 4.7 points, creating a 5.1-point difference between the groups.

The benefit reportedly began as early as two days after treatment.

These results closely followed Definium’s first Phase 3 anxiety trial, which involved 214 adults. In that study, the 100-microgram group improved by 11.6 points after 12 weeks, compared with a 6.2-point reduction in the placebo group.

Trial Participants 100 mcg DT120 (HAM-A reduction at 12 weeks) Placebo (HAM-A reduction at 12 weeks) Difference
First Phase 3 trial 214 adults 11.6 points 6.2 points 5.4 points
Second Phase 3 trial 245 adults 9.8 points 4.7 points 5.1 points

Seeing similar results across two trials gives the company stronger evidence that the effect was not limited to a single group of participants.

FDA Approval Is Still a Process

Definium plans to submit DT120 to the FDA in the first half of 2027. A successful submission would begin the review process, not guarantee approval or establish an exact date when the treatment would become available.

The FDA will evaluate more than whether anxiety scores improved. Regulators will also examine adverse events, dosing procedures, patient screening, monitoring requirements and whether the treatment’s benefits outweigh its risks.

Psychedelic trials face another challenge: most participants can tell whether they received an active psychedelic or a placebo. That can influence expectations and make it harder to separate the pharmacological effect from the experience surrounding it.

The new results are significant, but the complete data will be needed to understand how many participants responded, how many experienced lasting remission and which risks emerged across both trials.

Research Is Moving Forward. The Street Supply Hasn't Changed.

Blotter art and a seller's word can't tell you what's on a tab. Reagent testing can tell you whether it behaves like LSD or something else entirely.

Get LSD Test Kits →

Pharmaceutical LSD Is Not the Same as an Unverified Tab

Participants received a precisely manufactured compound at a measured dose in a controlled setting. They were screened before treatment and monitored throughout the dosing session.

A tab obtained outside a clinical study does not come with those controls. Blotter artwork, appearance and a seller’s description cannot establish whether it contains LSD, an LSD prodrug such as 1P-LSD, or a different compound entirely.

The LSD Spot Kit Package uses multiple reagent reactions to help determine whether a sample behaves consistently with LSD. The results can be compared with lab-verified reaction videos in the Transparency Harm Reduction App.

Identity and Dose Are Separate Questions

Clinical researchers know both the identity and dose of the drug they administer. Outside a study, those require different testing methods.

After screening identity with multiple reagents, an LSD QTest can estimate the quantity of LSD in a tab or liquid sample. It cannot identify an unknown substance or establish that a sample is safe.

Anyone learning how to test LSD should therefore begin with substance identification before moving to potency testing. For more comprehensive information, mail-in laboratory testing can analyze the compounds detected and, with the appropriate panel, quantify a submitted sample.

The LSD Testing Order:

  1. Identity First: Screen your sample with multiple reagents using the LSD Spot Kit Package
  2. Compare Your Results: Match your reactions against lab-verified reaction videos in the Transparency Harm Reduction App
  3. Then Dose: Estimate micrograms per tab or liquid sample with an LSD QTest
  4. Lab Analysis (Most Comprehensive): Submit a sample to Transparency Testing for compound identification and quantification

Remember: A QTest measures quantity. It doesn't identify an unknown substance. Always confirm identity before measuring dose.

What Happens Next

Two successful Phase 3 trials make DT120 one of the most advanced psychedelic treatments currently moving toward federal review.

⚠️ Important: The findings do not mean LSD is already an approved anxiety medication, nor do they turn unregulated LSD into a substitute for supervised treatment. They show that a controlled, pharmaceutical formulation may produce meaningful and lasting anxiety relief after a single monitored dose.

The next major step will be the company’s FDA submission and the agency’s review of the complete evidence.

Frequently Asked Questions

What is DT120?

DT120 is a fast-dissolving tablet containing lysergide, the pharmaceutical name for LSD, developed by Definium. In clinical trials, it was given once during a monitored dosing session rather than taken daily.

Is LSD approved to treat anxiety?

No. Definium plans to submit DT120 to the FDA in the first half of 2027. A submission starts the review process; it doesn't guarantee approval or set a date when the treatment would be available.

Does this research mean street LSD is safe to use for anxiety?

No. Trial participants received a precisely manufactured compound at a measured dose, with screening beforehand and monitoring throughout. A tab obtained outside a study has none of those controls, and it may contain LSD, a prodrug like 1P-LSD, or a different compound entirely.

What's the difference between reagent testing and an LSD QTest?

Reagent tests like those in the LSD Spot Kit Package help determine whether a sample behaves consistently with LSD. An LSD QTest estimates how much LSD is present but can't identify an unknown substance. Start with identity, then move to dose.

Know What It Is. Then Know How Much.

Clinical researchers never guess at identity or dose. You don't have to either. Screen with reagents, compare your results in the Transparency Harm Reduction App, and measure potency with a QTest.

Explore LSD Testing Tools →

Ships discreetly | Results in 60 seconds | Compare against lab-verified reaction videos

Related Resources

Learn more about testing LSD and psychedelic safety:

Sources